Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

6.00SEK
15 Dec 2017
Change (% chg)

-0.05kr (-0.83%)
Prev Close
6.05kr
Open
6.05kr
Day's High
6.15kr
Day's Low
5.90kr
Volume
12,853
Avg. Vol
184,838
52-wk High
10.20kr
52-wk Low
4.64kr

Chart for

About

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical... (more)

Overall

Beta: 1.47
Market Cap(Mil.): kr377.15
Shares Outstanding(Mil.): 62.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 60.10 16.04
EPS (TTM): -- -- --
ROI: -- 13.32 34.69
ROE: -- 19.86 15.46

BRIEF-Karolinska Development's Portfolio Company Gets FDA Approval

* KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY PROMIMIC RECEIVES FDA APPROVAL FOR HANANO SURFACE FOR USE ON DENTAL IMPLANTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 14 2017

BRIEF-Karolinska Development Divests Holding In Lipidor

* ‍ENTERED INTO AN AGREEMENT WITH A COMPENSATION IN FORM OF AN EARN OUT​

Dec 13 2017

BRIEF-Karolinska Development Q3 net result swings to profit of SEK 194.1 mln

* REG-KAROLINSKA DEVELOPMENT PUBLISHES INTERIM REPORT (JANUARY - SEPTEMBER 2017) AND REPORTS A POSITIVE RESULT FOR THE THIRD QUARTER

Oct 31 2017

BRIEF-Karolinska Development divests its holdings in Xspray

* KCIF CO-INVESTMENT FUND KB IS ALSO SELLING ITS SHARES IN THE FIRM

Oct 30 2017

BRIEF-Value of Karolinska Development's holdings in Umecrine Cognition increases

* REG-THE VALUE OF KAROLINSKA DEVELOPMENT'S HOLDINGS IN UMECRINE COGNITION INCREASES WITH SEK 196 MILLION OWING TO POSITIVE PHASE 1B DATA

Oct 16 2017

BRIEF-Karolinska Development's portfolio company secures financing

* REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY UMECRINE COGNITION SECURES FINANCING FOR CLINICAL DEVELOPMENT OF THE DRUG CANDIDATE GR3027 AGAINST SLEEP DISORDERS

Oct 04 2017

BRIEF-Karolinska Development's portfolio company BioArctic to list on Nasdaq Stockholm

* REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY BIOARCTIC INTENDS TO LIST ON NASDAQ STOCKHOLM

Sep 13 2017

BRIEF-Karolinska Development Q2 oper loss narrows to SEK 11.4 million

* SAID ON TUESDAY Q2 REVENUE SEK 560,000 VERSUS SEK 607,000 YEAR AGO

Aug 30 2017

BRIEF-Karolinska Development appoints Fredrik Järrsten as CFO

Aug 30 KAROLINSKA DEVELOPMENT AB: * SAID ON TUESDAY APPOINTED FREDRIK JÄRRSTEN AS CFO * JÄRRSTEN WILL REPLACE CHRISTIAN TANGE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 30 2017

BRIEF-Karolinska notes the planned listing of Xspray on Nasdaq First North

* REG-KAROLINSKA DEVELOPMENT NOTES THE PLANNED LISTING OF XSPRAY AB ON NASDAQ FIRST NORTH

Aug 25 2017

Earnings vs. Estimates